BCG PRIME

This is a randomized, controlled, multicenter trial that included 6112 immunologically vulnerable individuals aged over 60.

From the first inclusion to the end of their follow-up, the study took place in a period between September 2020 to June 2021.

*The trial was approved by the Utrecht Institutional Review Board (protocol NL74730.041.20) and registered in the European Clinical Trials Database (2020-003470-47) and in clinicaltrials.gov (NCT04537663).

Selected Publications

Koekenbier, E. L., Fohse, K., van de Maat, J. S., Oosterheert, J. J., van Nieuwkoop, C., Hoogerwerf, J. J., Grobusch, M. P., van den Bosch, M. A. A. J., van de Wijgert, J. H. H., Netea, M. G., Rosendaal, F. R., Bonten, M. J. M., Werkhoven, C. H. H. V., & BCG-PRIME study group (2023). Bacillus Calmette-Guérin vaccine for prevention of COVID-19 and other respiratory tract infections in older adults with comorbidities: a randomized controlled trial. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, 29(6), 781–788. https://doi.org/10.1016/j.cmi.2023.01.019